Bibliography

Accepted Articles

Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. *N Engl J Med*. 1995;332(2):80-85.

Anderson JL, Lutz JR, Gilbert EM, Sorensen SG, Yanowitz FG, Menlove RL, et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. *Am J Cardio*. 1985;55(4) p471-5.

Andersson B, Hamm C, Persson S, Wikstrom G, Sinagra G, Hjalmarson A, et al. Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment. *J Am Coll Cardiol*. 1994;23(6):1397-404.

Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group *Lancet*. 1997;349(9049) p375-80.

Ball SG, Hall AS, Mackintosh AF, et al. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators *Lancet*. 1993;342(8875) p821-8.

Barabino A, Galbariggi G, Pizzorni C, et al. Comparative effects of long-term therapy with captopril and ibopamine in chronic congestive heart failure in old patients. *Cardiology*. 1991;78:289-296.

Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. *Circulation*. 1996;94:2807-2816.

Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. *Circulation*. 1994;89(4) p1632-42.

Brown E J Jr, Chew PH, MacLean A, Gelperin K, Ilgenfritz JP, Blumenthal M. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Fosinopril Heart Failure Study Group. *Am J Cardio*. 1995;75(8) p596-600.

Bulpitt CJ, Fletcher AE, Dossegger L, Neiss A, Nielsen T, Viergutz S. Quality of life in chronic heart failure: cilazapril and captopril versus placebo. Cilazapril-Captopril Multicentre Group. *Heart*. 1998;79(6):593-8.

Bussmann WD, Storger H, Hadler D, et al. Long-term treatment of severe chronic heart failure with captopril: a double-blind randomized, placebo-controlled long-term study. *J Cardiovasc Pharmacol*. 1987;9(suppl. 2):S50-S60.

Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. *JAMA*. 1988;259(4):539-44.

Chalmers JP, West MJ, Cyran J, De La Torre D, Englert M, Kramar M, et al. Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study. *J Cardiovasc Pharmacol*. 1987;9 Suppl 3 pS89-97.

CIBIS Investigators and Committees A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS).. *Circulation*. 1994;90(4):1765-73.

CIBIS-II: The Cardiac Insufficiency Bisoprolol Study II: a randomised trial. *Lancet*. 1999;353(9146):9-13.

Cice G, Tagliamonte E, Ferrara L, Iacono A. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study *Eur Heart J.* 2000;21(15):1259-64.

Cleland JG, Erhardt L, Murray G, Hall AS, Ball SG. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators *Eur Heart J.* 1997;18(1):41-51.

Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, et al. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. *Journal of Cardiac Failure.* 1997;3(3) p173-9.

Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. *Circulation.* 1996;94:280-2806.

The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *N Engl J Med.* 1987;316(23):1429-35

Creager MA, Massie BM, Fascon DP, et al. Acute and long-term effects of Enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. *JACC.* 1985;6:163-70.

Cucchini F, Compostella L, Papalia D, de Domenico R, Iavernaro A, Zeppellini R [Chronic treatment of dilated cardiomyopathy by beta blocking agents. Clinical and hemodynamic follow-up]: <Original> Trattamento cronico della cardiomiopatia dilatativa con betabloccanti. Controllo clinico ed emodinamico a distanza. *Giornale Italiano Di Cardiologia.* 1988;18(10) p835-42.

Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Effects of carvedilol on left ventricular regional wall motion in patients with heart failure caused by ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. *J Card Fail.* 2000;6(1):11-8.

Eichhorn EJ, Domanski MJ, Adams K, et al. Effect of beta-blockade on mortality in African-Americans: The beta-blocker evaluation of survival trial. *Circulation.* 2000;102 (suppl 2)(18).

Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. *J Am Coll Cardiol.* 1994;24(5):1310-20.

Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. *Euro J Heart Failure.* 2001;3:469-479.

Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. *N Eng J Med.* 2001;344(18):1351-7.

Exner DV, Dries DL, Domanski MJ, et al. Enalapril therapy and outcome in Black versus White patients enrolled in the studies of left ventricular dysfunction. *Circulation.* 2000;102(18).

Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. *J Am Coll Cardiol.* 1994;23(4) p943-50.

Genth-Zotz S, Zotz RJ, Sigmund M, Hanrath P, Hartmann D, Bohm M, et al. MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing. *Eur J Heart Fail.* 2000;2(2) p175-81.

Ghose JC, Chakraborty S, Mondal M, Bhandari B. Effect of vasodilator therapy on mortality in chronic congestive heart failure. *Journal of the Association of Physicians of India.* 1993;41(5) p269-71.

Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. *Am J Med.* 1990;88(3) p223-9.

Giles TD, for Lisinopril Chronic Heart Failure Group. Lisinopril treatment of congestive heart failure-results of a placebo controlled trial. *Circulation*. 1990;82(suppl 4):III-323.

Gundersen T, Wiklund I, Swedberg K, Amtorp O, Remes J, Nilsson B. Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: results of a placebo-controlled trial. Ramipril Study Group. *Cardiovascular Drugs and Therapy*. 1995;9(4) p589-94.

Gustafsson I, Torppedersen C, Kober L, Gustafsson F, Hildebrandt P. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. *J Am Coll Cardiol*. 1999;34(N1. JUL):83-89.

Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy *Lancet*. 1997;349(9064) p1493-7.

Herlitz J, Waagstein F, Lindqvist J, Swedberg K, Hjalmarson A. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg Metoprolol Trial). *Am J Cardio*. 1997;80(9B) p40J-44J.

Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. *JAMA*. 2000;283(10) p1295-302.

Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet*. 1999;353(9169):2001-2007.

Jerie P, Kremer HJ, Uhlir O, Widimsky J. [A Czech and Slovak interventional study of spirapril (the CASSIS study). A randomized, double-blind, multicenter, placebo-controlled study in chronic heart failure]: <Original> Ceska a slovenska intervencni studie se spiraprilem (studie CASSIS). Randomizovana, dvojiteslepa, multicentricka studie, kontrolovana aktivne i placebem chronickeho srdecniho selhani. Za resitele studie CASSIS. *Vnitrni Lekarstvi*. 1997;43(6) p351-8.

Keren G, Pardes A, Eschar Y, Koifman B, Scherez J, Geleranter I, et al. One-year clinical and echocardiographic follow-up of patients with congestive cardiomyopathy treated with captopril compared to placebo. *Israel Journal of Medical Sciences*. 1994;30(1) p90-8.

Kjekshus J, Swedberg K. Enalapril for congestive heart failure. *Am J Cardio*. 1989;63(8) p26D-32D.

Kleber FX, Laube A, Osterkorn K, et al. Captopril in mild to moderate heart failure after 18 months: effects on morbidity and mortality. *JACC*. 1987;9:42A (Abstr).

Kleber FX, Niemoller L, Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial. *British Heart Journal*. 1992;67(4) p289-96.

Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. *N Engl J Med*. 1995;333(25) p1670-6.

Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. *Circulation*. 1995;92(6) p1499-506.

Magnani B. Converting enzyme inhibition and heart failure. *Am J Med*. 1988;84(3A) p87-91.

Magnani B, Magelli C. Captopril in mild heart failure: preliminary observations of a long-term, double-blind, placebo-controlled multicentre trial. *Postgraduate Medical Journal*. 1986;62 Suppl 1 p153-8.

Moye LA, Pfeffer MA, Wun CC, Davis BR, Geltman E, Hayes D, et al. Uniformity of captopril benefit in the SAVE study: Subgroup analysis. *Eur Heart J*. 1994;15(SUPPL. B):2-8.

Newman TJ, Maskin CS, Dennick LG, Meyer JH, Hallows BG, Cooper WH. Effects of captopril on survival in patients with heart failure. *Am J Med*. 1988;84(3A) p140-4.

Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. *N Engl J Med*. 1996;334(21):1349-55.

Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med*. 2001;344(22):1651-8.

Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. *Circulation*. 1996;94(11):2793-9.

Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med*. 1992;327(10) p669-77.

Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators. *J Am Coll Cardiol*. 1993;22(6):1557-63.

Pitt B, Yusuf S, for the SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD) subgroup results. *J Am Coll Cardiol*. 1992;19:215A.

Plehn JF, Krause-Steinrauf H, Anand IS, et al. Effect of race on cause-specific cardiovascular mortality in BEST. *Circulation*. 2000;102 (suppl 2)(18).

Pouleur HG, Konstam MA, Udelson JE, Rousseau MF. Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction. The SOLVD Investigators. *J Am Coll Cardiol*. 1993;22(4 Suppl A):43A-48A.

Sharpe DN, Murphy J, Coxon R, et al. Enalapril in patients with chronic heart failure: a placebo controlled randomized double-blind study. *Circulation*. 1984;70:271-8.

Swedberg K, Kjekshus J, Snapinn SOLVD Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. *Eur Heart J*. 1999;20(2) p136-9.

The Beta-Blocker Evaluation of Survival Trial Investigators (BEST). A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. *N Engl J Med*. 2001;344(22):1659-67.

The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. *Circulation*. 2000;101(4) p378-84.

The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med*. 1991;325(5):293-302.

Torp-Pedersen C, Kober L, Carlsen J. Angio-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study. *Am Heart J*. 1996;132(1 Pt 2 Su):235-43.

van Veldhuisen DJ, Genth-Zotz S, Brouwer J, Boomsma F, Netzer T, Man T, Veld AJ, et al. High-versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. *J Am Coll Cardiol*. 1998;32(7) p1811-8.

Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. *Lancet*. 1993;342(8885) p1441-6.

Wedel H, DeMets D, Deedwania P, et al. Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HR trial. *Am Heart J*. 2001;142:502-11.

Widimsky J, Kremer HJ, Jerie P, Uhlir O. Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active-controlled, double-blind multicentre trial in patients with congestive heart failure. *European Journal of Clinical Pharmacology*. 1995;49(1-2) p95-102.

Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. *J Am Coll Cardiol*. 1993;21(5):1094-100.

Witchitz S, Cohen-Solal A, Dartois N, Weisslinger N, Juste K, Darmon J Y. Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties. The CELICARD Group. *Am J Cardio*. 2000;85(12) p1467-71.

Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. *Circulation*. 1991;84(6):2426-41.

Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. *N Engl J Med*. 2001;344(18):1358-65.

Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Lukas MA, Young ST. Response of black heart failure patients to carvedilol [abstract]. *J Am Coll Cardiol*. 1997;29:284A.

Yusuf S, Nicklas JM, Timmis G, Breneman G, Jafri SM, Duvernoy WFC, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. *N Engl J Med*. 1992;327(10):685-691.

Rejected Articles

Acanfora D, Lanzillo T, Papa A, Longobardi G, Furgi G, Rengo C, et al. Congestive heart failure in elderly patients: controlled study of delapril versus captopril. *Am J Cardiol*. 1995;75(18): 37F-43F.

Afzal A, Ananthasubramaniam K, Sharma N, al-Malki Q, Ali AS, Jacobsen G, et al. Racial differences in patients with heart failure. *Clin Cardiol*. 1999;22(12):791-4.

Afzal A, Brar JS, Ali AS, et al. Racial differences in patients with chest pain syndrome and abnormal coronary angiogram. *Chest*. 1997;112:245.

Ajayi AA, Balogun MO, Oyewo EA, Ladipo GO. Enalapril in African patients with congestive cardiac failure. *Br J Clin Pharmacol*. 1989;27(3) p400-3.

Akinkugbe OO, Nicholson GD, Cruickshank JK. Heart disease in blacks of Africa and the Caribbean. Saunders E. (editor). *Cardiovascular Disease in Blacks*. Philadelphia: F.A. Davis, 1991:377-91.

Alexander M, Grumbach K, Selby J, et al. Hospitalization for congestive heart failure: explaining racial differences. *JAMA*. 1990;263:2344-6.

Ambrosioni E, Borghi C, Magnani B. Survival of myocardial infarction long-term evaluation (SMILE) study: rationale, design, organization, and outcome definitions. *Control Clin Trials*. 1994;15(3):201-10.

Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. *N Engl J Med*. 1995;332(2):80-85.

American Heart Association. Heart and Stroke Facts: 1996 Statistical Supplement. Dallas, Texas: American Heart Association, 1996, 15.

Anderson F, Nilsson B, Gundersen T, Swedberg K, Amtorp O, Remes J. The effect on healthcare costs of adding ramipril to conventional therapy for patients with congestive heart failure. *Br J Med Econ*. 1995;8(3):125-135.

Anderson JL, Lutz JR, Gilbert EM, Sorensen SG, Yanowitz FG, Menlove RL, et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. *Am J Cardio*. 1985;55(4) p471-5.

Andersson B, Hamm C, Persson S, Wikstrom G, Sinagra G, Hjalmarson A, et al. Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment. *J Am Coll Cardiol*. 1994;23(6):1397-404.

Arcensio SR, Barretto AC, Szambock F, Mady C, Arteaga E, da Luz PL, et al. [Comparative study between ibopamine and captopril in mild and moderate heart failure. A double-blind study]. *Arq Bras Cardiol*. 1994;63(5):409-13.

Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. *Am J Cardio*. 1997;80(2) p207-9.

Aronow WS, Ahn C, Kronzon J. Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and eletrocardiographic evidence of left ventricular hypertrophy. *Am J Cardiol*. 1991;67:295-299.

Aronow WS, Greenfield RS, Alimadadian H, et al. Effect of the vasodilator trimazosin vs. placebo on exercise performance in chronic left ventricular failure. *Am J Cardiol*. 1977;40:789-793.

Aronow WS, Lurie M, Turbow M, et al. Effect of prazosin vs. placebo on chronic left ventricular heart failure. *Circulation*. 1979;59:344-350.

Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. *Lancet*. 1997;349(9049):375-80.

Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine—is this a cause for concern? *Arch Int Med.* 2000;160(N5):685-693.

Ball SG, Hall AS, Mackintosh AF, et al. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. *Lancet.* 1993;342(8875) p821-8.

Bangdiwala SI, Weiner DH, Bourassa MG, Friesinger GC 2d, Ghali JK, Yusuf S. Studies of Left Ventricular Dysfunction (SOLVD) Registry: rationale, design, methods and description of baseline characteristics. *Am J Cardiol.* 1992;70(3):347-53.

Barabino A, Galbariggi G, Pizzorni C, et al. Comparative effects of long-term therapy with captopril and ibopamine in chronic congestive heart failure in old patients. *Cardiology*. 1991;78:289-296.

Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. *Am J Cardio.* 1995;76(17):1259-1265.

Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. *Circulation.* 1999;99(20):2658-64.

Bayliss J, Canepa-Anson R, Norell M, Poole-Wilson P, Sutton G. The renal response to neuroendocrine inhibition in chronic heart failure: double-blind comparison of captopril and prazosin. *Eur Heart J.* 1986;7(10):877-84.

Beermann B, Nyquist O, Hoglund C, Jacobsson KA, Naslund U, Jensen-Urstad M. Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study. *Eur J Clin Pharmacol.* 1993;45(3):241-6.

Behrens S, Ney G, Fisher SG, Fletcher RD, Franz MR, Singh SN. Effects of amiodarone on the circadian pattern of sudden cardiac death (Department of Veterans Affairs Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy). *Am J Cardiol.* 1997;80(1):45-8.

Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. *Circulation.* 1996;94(4):690-7.

Beneficial effects of captopril on prognosis in patients with acute myocardial infarction. *Chinese Journal of Cardiology.* 1996;24(3):187-190.

Berger PB, Holmes DR Jr, Ohman EM, O'Hanesian MA, Murphy JG, Schwartz RS, et al. Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR). *J Am Coll Cardiol.* 1996;27(1):1-7.

Bergler-Klein J, Sochor H, Pouleur H, Pacher R, Porenta G, Glogar D. Safety of concomitant potassium-sparing diuretics in angiotensin-converting enzyme inhibitor therapy in severe congestive heart failure. *J Cardiovasc Pharmacol.* 1994;24(2):194-198.

The BEST Steering Committee, Design of the Beta-Blocker Evaluation Survival Trial (BEST). *Am J Cardio.* 1995;75(17) p1220-3.

The Beta-Blocker Evaluation of Survival Trial Investigators (BEST). A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. *N Engl J Med.* 2001;344(22):1659-67.

Beynon JH, Pathy MS. An open, parallel group comparison of quinapril and captopril, when added to diuretic therapy, in the treatment of elderly patients with heart failure. *Curr Med Res Opin.* 1997;13(10) p583-92.

Boccanelli A, Zachara E, Liberatore SM, Carboni GP, Prati PL. Addition of captopril versus increasing diuretics in moderate but deteriorating heart failure: a double-blind comparative trial. *Postgrad Med J*. 1986;62 Suppl 1:184-7.

Bohler S, Saubadu S, Scheldewaert R, Figulla HR. Betaxolol versus carvedilol in chronic heart failure (BETACAR study). Rationale and design. *Arzneimittelforschung*. 1999;49(4):311-7.

Borghi C, Ambrosioni E, Magnani B. Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute myocardial infarction. The SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. *Am J Cardiol*. 1996;78(3):317-22.

Borghi C, Bacchelli S, Esposti DD, Bignamini A, Magnani B, Ambrosioni E. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. *Am J Hypertens*. 1999;12(7):665-72.

Borghi C, Marino P, Zardini P, Magnani B, Collatina S, Ambrosioni E. Short- and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: results from the Fosinopril in Acute Myocardial Infarction Study. FAMIS Working Party. *Am Heart J*. 1998;136(2):213-25.

Borghi C, Magelli C, Costa FV, Magnani B, Ambrosioni E. Captopril improves hemodynamic response to static exercise in patients with congestive heart failure: a double-blind, placebo-controlled, randomized trial. *Clin Cardiol*. 1990;13(5):329-34.

Bounhoure JP, Bottineau G, Lechat P, et al. Apport du perindopril au traitement de l'insuffisance cardiaque chronique congestive. *Arch Mal Coeur*. 1989;82:73-8.

Bourassa MG, Gurne O, Bangdiwala SI, Ghali JK, Young JB, Rousseau M, Johnstone DE, Yusuf S. Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. *J Am Coll Cardiol*. 1993;22(4 Suppl A):14A-19A.

Braunwald E. Expanding indications for beta-blockers in heart failure. *N Engl J Med*. 2001;344(22):1711-12.

Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. *Circulation*. 1996;94:2807-2816.

Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. *Circulation*. 1994;89(4) p1632-42.

Brown EJ Jr, Chew PH, MacLean A, Gelperin K, Ilgenfritz JP, Blumenthal M. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Fosinopril Heart Failure Study Group. *Am J Cardio*. 1995;75(8):596-600.

Buchwald A, Unterberg C, van der Does R, Wiegand V. [Acute hemodynamic effects of the vasodilator beta blocker carvedilol in heart failure]. *Z Kardiol*. 1990;79(6):424-8.

Bulpitt CJ, Fletcher AE, Dossegger L, Neiss A, Nielsen T, Viergutz S. Quality of life in chronic heart failure: cilazapril and captopril versus placebo. Cilazapril-Captopril Multicentre Group. *Heart*. 1998;79(6):593-8.

Bussmann WD, Storger H, Hadler D, et al. Long-term treatment of severe chronic heart failure with captopril: a double-blind randomized, placebo-controlled long-term study. *J Cardiovasc Pharmacol*. 1987;9(suppl. 2):S50-S60.

Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). *Am Heart J*. 1997;134(1):44-54.

Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. *JAMA*. 1988;259(4):539-44.

Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. *J Am Coll Cardiol*. 1983;63:755-763.

Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. *J Card Fail*. 1999;5(3):178-87.

Chalmers JP, West MJ, Cyran J, De La Torre D, Englert M, Kramar M, et al. Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study. *J Cardiovasc Pharmacol*. 1987;9 Suppl 3 pS89-97.

Chantrel F, Moulin B, Hannedouche T. Blood pressure, diabetes and diabetic nephropathy. *Diabetes Metab*. 2000;26 Suppl 4:37-44.

Chizzola PR, Freitas HF, Caldas MA, da Costa JM, Meneghetti C, Marinho NV, et al. Effects of carvedilol in heart failure due to dilated cardiomyopathy. Results of a double-blind randomized placebo-controlled study (CARIBE study). *Arquivos Brasileiros De Cardiologia*. 2000;74(3) p233-42.

Chrysant SG, Gollub S, Dunn MI, et al. Hemodynamic and metabolic effects of enalapril in patients with heart failure. *Clin Cardiol*. 1985;8:585-590.

CIBIS Investigators and Committees, A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). *Circulation*. 1994;90(4) p1765-73.

CIBIS II Investigators and Committee, The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet*. 1999;353(9146):9-13.

The CIBIS II Scientific Committee. Design of the cardiac insufficiency bisoprolol study II (CIBIS II). *Fund Clin Pharmacol*. 1997;11:38-42.

Cice G, Tagliamonte E, Ferrara L, Iacono A. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study. *Eur Heart J*. 2000;21(15):1259-64.

Circo A, Platania F, Mangiameli S, Putignano E. Multicenter, randomized, placebo-controlled, double-blind study of the safety and efficacy of oral delapril in patients with congestive heart failure. *Am J Cardiol*. 1995;75(18):18F-24F.

Cleland JG, Armstrong P, Horowitz JD, Massie B, Packer M, Poole-Wilson PA, et al. Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study. *Eur J Heart Fail*. 1999;1(1):73-9.

Cleland JG, Dargie HJ, Gillen G, Robertson I, East BW, Ball SG, et al. Captopril in heart failure: a double-blind study of the effects on renal function. *J Cardiovasc Pharmacol*. 1986;8(4):700-6.

Cleland JG, Erhardt L, Murray G, Hall AS, Ball SG. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. *Eur Heart J*. 1997;18(1):41-51.

Cleland JG, Pennel D, Ray S, Murray G, MacFarlane P, Cowley A, et al. The carvedilol hibernation reversible ischaemia trial; marker of success (CHRISTMAS). The CHRISTMAS Study Steering Committee and Investigators. *Eur J Heart Fail*. 1999;1(2):191-6.

Cleland JG, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M, et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. *Eur J Heart Fail*. 1999;1(3) p211-7.

Cleland JGF, Dargie HJ, Hodsman GP, et al. Captopril in heart failure: a double blind controlled trial. *Br Heart J*. 1984;52:530-5.

Cleland JGF, Dargie HJ, Ball SG, et al. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J. 1985;54:305-311.

Cleland JGF, Shah D, Krikler S, Frost G, Oakley CM. Angiotensin-converting enzyme-inhibitors, left-ventricular dysfunction, and early heart-failure. *Am J Cardio*. 1992;70(N10. OCT 8):C55-C61.

Clement DL, De Buyzere M, Tomas M, Vanavermaete G. Long-term effects of clinical outcome with low and high dose in the Captopril in Heart Insufficient Patients Study (CHIPS). *Acta Cardiol*. 2000;55(1):1-7.

Cohn JN, Archibald DG, Ziesche S, et al. Effects of vasodilator therapy on mortality in chronic congestive heart failure. *N Engl J Med*. 1986;314:1547-1552.

Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, et al. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. *Journal of Cardiac Failure*. 1997;3(3) p173-9.

Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. *N Engl J Med*. 1998;339(25):1810-6.

Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. *N Engl J Med*. 1991;325:303-10.

Cohn JN, Tognoni G, Glazer RD, Spormann D, Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. *J Card Fail*. 1999;5(2):155-60.

Colfer HT, Ribner HS, Gradman A, Hughes CV, Kapoor A, Laidlaw JC. Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. The Benazepril Heart Failure Study Group. *Am J Cardio*. 1992;70(3) p354-8.

Colfer HT, Ribner HS, Gradman A, et al. Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. *Am J Cardiol*. 1992;70:354-358.

Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. *Circulation*. 1996;94:280-2806.

Colucci WS, Sonnenblick EH, Adams KF, Berk M, Brozena SC, Cowley AJ, et al. Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators. *J Am Coll Cardiol*. 1993;22(4 Suppl A):113A-118A.

Colucci WS, Wynne J, Holman BL, et al. Long-term therapy of heart failure with prazosin: a randomized double blind trial. *Am J Cardiol*. 1980;45:337-344.

Comstock GW. An epidemiological study of blood pressure levels in a biracial community in the southern United States. *Am J Hygiene*. 1957;65:271-315.

Conradson TB. Hydralazine vs. placebo in CHF-preliminary results from a multicenter long-term study in Sweden. *Acta Med Scand*. 1981;652(suppl):177-180.

Copie X, Pousset F, Lechat P, Jaillon P, Guize L, Le Heuzey JY. Effects of beta-blockade with bisoprolol on heart rate variability in advanced heart failure: analysis of scatterplots of R-R intervals at selected heart rates. *Am Heart J*. 1996;132(2 Pt 1):369-75.

Coughlin SS, Myers L, Michaels RK. What explains black-white differences in survival in idiopathic dilated cardiomyopathy? The Washington, DC, dilated cardiomyopathy study. *Journal of the National Medical Association*. 1997;89(N4):277-282.

Council on Ethical and Judicial Affairs. Black-white disparities in health. *JAMA*. 1990;263:2344-6.

Cowley AJ, Stainer K, Wynne RD, Rowley JM, Hampton JR. Comparison of the effects of captopril and enoximone in patients with severe heart failure: a placebo controlled double-blind study. *Int J Cardiol*. 1989;24(3):311-6.

Creager MA, Massie BM, Fascon DP, et al. Acute and long-term effects of Enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. JACC. 1985;6:163-70.

Cucchini F, Compostella L, Papalia D, de Domenico R, Iavernaro A, ZeppelliniR. [Chronic treatment of dilated cardiomyopathy by beta blocking agents. Clinical and hemodynamic follow-up]: <Original> Trattamento cronico della cardiomiopatia dilatativa con betabloccanti. Controllo clinico ed emodinamico a distanza. *Giornale Italiano Di Cardiologia*. 1988;18(10) p835-42.

Currie PJ, Kelly MJ, McKenzie A, Harper RW, Lim YL, Federman J, et al. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. *J Am Coll Cardiol*. 1984;3(1):203-9.

Davies RF, Beanlands DS, Nadeau C, Phaneuf D, Morris A, Arnold JM, et al. Enalapril versus digoxin in patients with congestive heart failure: a multicenter study. Canadian Enalapril Versus Digoxin Study Group. *J Am Coll Cardiol*. 1991;18(7):1602-9.

Debock VD, Mets T, Romagnoli M, Dende MP. Captopril treatment of chronic heart-failure in the very old. *Journals of Gerontology*. 1994;49(N3. MAY):M148-M152.

Denis B, Machecourt J. Renitec et insuffisance cardiaque. *Tempo Medical*. 1985;5:40-3.

Dickstein K, Aarsland T. Effect on exercise performance of enalapril therapy initiated early after myocardial infarction. Nordic Enalapril exercise Trial. *J Am Coll Cardiol*. 1993;22(4):975-83.

Dickstein K, Barvik S, Aarsland T. Effect of long-term enalapril therapy on cardiopulmonary exercise performance in men with mild heart failure and previous myocardial infarction. *J Am Coll Cardiol*. 1991;18:596-602.

Diercks GF, Janssen WM, van Boven AJ, Bak AA, de Jong PE, Crijns HJ, et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial PREVEND IT). *Am J Cardiol*. 2000;86(6):635-8.

Dorszewski A, Gohmann E, Dorszewski B, Werner GS, Kreuzer H, Figulla HR. Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study. *Journal of Cardiac Failure*. 1997;3(2) p91-6.

Dossegger L, Bernink, Braun, Burger, Calvert, Deimann, et al. Comparison of the effects of cilazapril and captopril versus placebo on exercise testing in chronic heart-failure patients—a double-blind, randomized, multicenter trial. *Cardiology*. 1995;86(S1):34-40.

Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. *J Am Coll Cardiol*. 1997;29(5):1060-6.

Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Effects of carvedilol on left ventricular regional wall motion in patients with heart failure caused by ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. *J Card Fail*. 2000;6(1):11-8.

Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). *Lancet*. 1994;344(8921):493-8.

Drexler H, Banhardt U, Meinertz T, Wollschlager H, Lehmann M, Just H. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebo-controlled trial. *Circulation*. 1989;79(3) p491-502.

Dries DL, Exner DV, Gersh J, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction [published erratum appears in *N Engl J Med* 1999 Jul 22;341(4):298]. *N Engl J Med*. 1999;340(8):609-16.

Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. *J Am Coll Cardiol*. 2000;35(3) p681-9.

East MA, Peterson ED, Shaw LK, et al. Racial differences in the outcome of patients with diastolic heart failure: Results from the Duke Databank of Cardiovascular Disease. *Circulation*. 2000;102 (suppl)(18).

Eichhorn EJ, Domanski MJ, Adams K, et al. Effect of beta-blockade on mortality in African-Americans: The beta-blocker evaluation of survival trial. *Circulation*. 2000;102 (suppl 2)(18).

Eichhorn EJ, Domanski MJ, Bristow MR, et al. Hemodynamic, myocardial functional and neurohormonal responses to beta-blockade in Black vs. Non-Black patients in BEST. *Circulation*. 2000;102 (suppl II)(18).

Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. *J Am Coll Cardiol*. 1994;24(5):1310-20.

Enalapril CHF Investigators. Long-term effects of enalapril in patients with congestive heart failure: a multicenter, placebo-controlled trial. *Heart Failure*. 1987;3:102-107.

Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. *Circulation*. 1985;72(3) p536-46.

Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. *Euro J Heart Failure*. 2001;3:469-479.

Eriksson SV, Offstad J, Kjekshus J. M-mode echocardiography in patients with severe congestive heart failure. A subgroup analysis in the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *Drugs*. 1990;39 Suppl 4:43-8; discussion 53-4.

Erlemeier HH, Kupper W, Bleifeld W. Comparison of hormonal and haemodynamic changes after long-term oral therapy with pimobendan or enalapril--a double-blind randomized study. *Eur Heart J*. 1991;12(8):889-99.

Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patiens with left ventricular dysfunction. *N Eng J Med*. 2001;344(18):1351-7.

Exner DV, Dries DL, Domanski MJ, et al. Enalapril therapy and outcome in Black versus White patients enrolled in the studies of left ventricular dysfunction. *Circulation*. 2000;102(18).

Fagan TC. Diltiazem: its place in the antihypertensive armamentarium. *J Cardiovasc Pharmacol*. 1991;18 Suppl 9:S26-31.

Fagerberg B. Screening, endpoint classification, and safety monitoring in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Eur J Heart Fail*. 2000;2(3):315-24.

Fang J, Madhavan S, Alderman MH. The association between birthplace and mortality from cardiovascular causes among black and white residents of New York City. *N Engl J Med*. 1996;335:1545-51.

Figulla HR, Luig H, Nieschlag F, Kreuzer H. [Clinical and hemodynamic effects of nisoldipine and captopril in heart failure: a double-blind comparative study of long and short-term effects]. *Z Kardiol*. 1987;76(3):167-74.

Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. *J Am Coll Cardiol*. 1994;23(4) p943-50.

Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. *Lancet*. 2000;355(9215) p1575-81.

Fletcher AE, Bulpitt CJ, Chase DM, Collins WC, Furberg CD, Goggin TK, et al. Quality of life with three antihypertensive treatments. Cilazapril, atenolol, nifedipine. *Hypertension*. 1992;19(6 Pt 1):499-507.

Forman DE, Chander RB, Lapane KL, Shah P, Stoukides J. Evaluating the use of angiotensin-converting enzyme inhibitors for older nursing home residents with chronic heart failure. *JAGS*. 1998;46(12) p1550-4.

Franciosa JA, Cohn JN. Sustained hemodynamic effects without tolerance during lon-term isosorbide dinitrate treatment of chronic left ventricular failure. *Am J Cardiol*. 1980;45:648-654.

Franciosa JA, Jordan RA, Wilen MM, et al. Minoxidil in patients with chronic left heart failure: contrasting hemodynamic and clinical effects in a controlled trial. *Circulation*. 1984;70:63-68.

Franciosa JA, Nordstrom LA Cohn JN. Nitrate therapy for congestive heart failure. *JAMA*. 1978;240:443-446.

Franciosa JA, Weber KT, Levine TB, et al. Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo. *Am Heart J*. 1982;104:587-594.

Franciosa JA, Wilen MM, Jordan RA. Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure. *J Am Coll Cardiol*. 1985;5(1) p101-7.

Francis CK. Report of the NHLBI working group on research in coronary heart disease in blacks: Issues and challenges. *J Nat Med Assoc*. 1995;87(suppl):597-603.

Francis CK. Heart failure in elderly African-Americans. *Am J Geriatr Cardiol*. 1997;6(5):50-68.

Fuchs W. Comparison of the safety and efficacy of delapril with captopril in outpatients with congestive heart failure. *Am J Cardiol*. 1995;75(18):29F-36F.

Funck-Brentano C, Lancar R, Le Heuzey JY, Lardoux H, Soubrie C, Lechat P. Predictors of medical events in patients enrolled in the cardiac insufficiency bisoprolol study (CIBIS): a study of the interactions between beta-blocker therapy and occurrence of critical events using analysis of competitive risks. *Am Heart J*. 2000;139(2 Pt 1) p262-71.

Gallagher EJ, Viscoli CM, Horwitz RiI The relationship of treatment adherence to the risk of death after myocardial-infarction in women. *JAMA*. 1993;270(N6):742-744.

Gambassi G, Forman DE, Lapane KL, Mor V, Sgadari A, Lipsitz LA, et al. Management of heart failure among very old persons living in long-term care: has the voice of trials spread? The SAGE Study Group. *Am Heart J*. 2000;139(1 Pt 1) p85-93.

Gambassi G, Lapane KL, Sgadari A, Carbonin P, Gatsonis C, Lipsitz LA, et al. Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. *Arch Intern Med*. 2000;160(1) p53-60.

Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. *JAMA*. 1995;273(18):1450-1456.

Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. *Arch Intern Med*. 1999;159(16):1939-45.

Gattis WA, Larsen RL, Hasselblad V, Bart BA, O'Connor CM. Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure? *Am Heart J*. 1998;136(1) p43-8.

Gavazzi A, Marioni R, Campana C, Montemartini C. Comparative trial of quinapril versus captopril in mild to moderate congestive heart failure. Quinapril/Captopril Congestive Heart Failure Study Group. *J Hypertens Suppl*. 1994;12(4):S89-93.

Genth-Zotz S, Zotz RJ, Sigmund M, Hanrath P, Hartmann D, Bohm M, et al. MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing. *Eur J Heart Fail*. 2000;2(2) p175-81.

Geronimus AT, Bound J, Waidmann TA, et al. Excess mortality among blacks and whites in the United States. *N Engl J Med*. 1996;335:1552-8.

Gerstein HC, Yusuf S, Mann JFE, Hoogwerf B, Zinman B, Held C, et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the hope study and micro-hope substudy. *Lancet*. 2000;355(N9200. JAN 22):253-259.

Ghali JK, Kadakia S, Cooper R, et al. Precpitating factors leading to decompensation of heart failure: traits among urban blacks. *Arch Intern Med.* 1988;148:2013-6.

Ghali JK, Pina IL, Gottlieb SS, et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). *Circulation*. 2002;105(13):1585-91.

Gheorghiade M, Benatar D, Konstam MA, Stoukides CA, Bonow RO. Pharmacotherapy for systolic dysfunction: a review of randomized clinical trials. *Am J Cardio.* 1997;80(N8B,SI):H14-H27.

Ghose JC, Chakraborty S, Mondal M, Bhandari B. Effect of vasodilator therapy on mortality in chronic congestive heart failure. *Journal of the Association of Physicians of India*. 1993;41(5) p269-71.

Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. *Am J Med*. 1990;88(3) p223-9.

Giles TD, for Lisinopril Chronic Heart Failure Group. Lisinopril treatment of congestive heart failure-results of a placebo controlled trial. *Circulation*. 1990;82(suppl 4):III-323.

Giles TD, Katz R, Sullivan JM, Wolfson P, Haugland M, Kirlin P, et al. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group. *J Am Coll Cardiol*. 1989;13(6):1240-7.

Gilligan DM, Chan WL, Joshi J, Clarke P, Fletcher A, Krikler S, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 1993;21(7):1672-9.

Gillum RF. The epidemiology of cardiovascular disease in black Americans [editorial; comment] *N Engl J Med*. 1996;335(21):1597-9.

Gillum RF. Coronary heart disease in black populations. I. Mortality and morbidity. *Am Heart J*. 1982;104:839-51.

Gillum RF. Epidemiology of hypertension in African American women. *Am Heart J.* 1986;131:385-95.

Gillum RF. Stroke in blacks. *Stroke*. 1988;19:1-9.

Gillum RF. Sudden coronary death in the United States. *Circulation*. 1989;79:756-65.

Gillum RF. Cardiovascular disease in the United States: an epidemiologic overview. Saunders E. (editor): *Cardiovascular Diseases in Blacks.* Philadelphia: F.A. Davis, 1991;3-16.

Gillum RF. Epidemiology of heart failure in the United States. *Am Heart J.* 1993;126:1042-1047.

Gillum RF. Trends in acute myocardial infarction and coronary heart disease death in the United States. *J Am Coll Cardiol*. 1994;23:1273-7.

Gillum RF, Ingram DI. The relation between residence in the Southeast region of the United States and stroke incidence and death: the NHANES I Epidemiologic Follow-up Study. *Am J Epidemiol*. 1996;144:665-73.

Goldstein S, Hjalmarson A. The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT-HF Trial. *Clinical Cardiology*. 1999;22 Suppl 5 pV30-5.

Gordon M. Evaluation of the Efficacy and Safety of Ramipril (HOE 498) in Patients with Congestive Heart Failure in a Placebo-controlled Trial.(unpublished report) 1991.

Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockers on mortality among high risk and low risk patients after myocardial infarction. *N Engl J Med*. 1998;339:489-97.

Gretler DD, Fumo MT, Nelson KS, et al. Ethnic differences in circadian hemodynamic profile. *Am J Hypertens.* 1994;7:7-14.

Gundersen T, Wiklund I, Swedberg K, Amtorp O, Remes J, Nilsson B. Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: results of a placebo-controlled trial. Ramipril Study Group. *Cardiovascular Drugs and Therapy.* 1995;9(4) p589-94.

Gustafsson I, Torppedersen C, Kober L, Gustafsson F, Hildebrandt P. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. *J Am Coll Cardiol.* 1999;34(N1. JUL):83-89.

Habte B. The efficacy of hydrochlorothiazide, timolol and enalapril in Ethiopians with essential hypertension. *Ethiop Med J.* 1992;30(3):163-7.

Hager WD, Davis BR, Riba A, Moye LA, Wun CC, Rouleau JL, et al. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. *Am Heart J.* 1998;135(3):406-13.

Hahn B, Strauer BE. The influence of beta-adrenoceptor blockade on left ventricular function. *Br J Clin Pharmacol.* 1982;13(Suppl 2):305S-307S.

Haiat R, Piot O, Gallois H, Hanania G. Blood pressure response to the first 36 hours of heart failure therapy with perindopril versus captopril. French General Hospitals National College of Cardiologists. *J Cardiovasc Pharmacol.* 1999;33(6):953-9.

Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. *Lancet.* 1997;349(9064):1493-7.

Hall AS, Winter C, Bogle SM, et al. The Acute Infarction Ramipril Efficacy (AIRE) Study: rationale, design, organization, and outcome definitions. *J Cardiovasc Pharmacol.* 1991;18(Suppl 2):S105-S109.

Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. *J Am Coll Cardiol.* 1995;25(5):1154-61.

Hall WD, Kusek JW, Kirk KA, Appel LJ, Schulman G, Agodoa LY, et al. Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American study of kidney disease and hypertension pilot study. *American Journal of Kidney Diseases.* 1997;29(N5):720-728.

Hammond IW, Alderman MH, Devereux RB. Contrast in cardiac anatomy and function between black and white patients with hypertension. *J Natl Med Assoc.* 1984;76:247-255.

Hampton JR. Choosing the right beta-blocker. A guide to selection. *Drugs.* 1994;48(4):549-68.

Han YL, Tong M, Jing Qm, Hu XL, Liu JQ. Combined therapy of captopril and spironolactone for refractory congestive-heart-failure. *Chinese Medical Journal.* 1994;107(N9. SEP):688-692.

Hansen JF, Hagerup L, Sigurd B, Pedersen F, Mellemgaard K, Pedersen-Bjergaard O, et al. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Danish Verapamil Infarction Trial (DAVIT) Study Group. *Am J Cardiol.* 1997;79(6):738-41.

Harper RW, Calzton H, Middlebrook K, et al. The acute and chronic haemodynamic effects of prazosin in severe congestive heart failure. *Med J Aust.* 1980;2(suppl):36-38.

Hasford J, Bussmann WD, Delius W, Kopcke W, Lehmann K, Weber E. Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure. *Z Kardiol.* 1991;80 Suppl 2:21-7.

Havranek EP, Abrams F, Stevens E, Parker K. Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. *Arch Intern Med.* 1998;158(18):2024-8.

Haywood IJ. Coronary heart disease mortality/morbidity and risk in blacks. I. Clinical manifestations and diagnostic criteria: the experience with the Beta Blocker Heart Attack Trial. *Am Heart J*. 1984;108:787-93.

He J, Whelton PK. Epidemiology and prevention of hypertension. *Med Clin North Am.* 1997;81(5): 1077-97.

Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. *J Am Coll Cardiol*. 1997;30:27-34.

Herholz H, Goff DC, Ramsey DJ, Chan FA, Ortiz C, Labarthe DR, et al. Women and Mexican Americans receive fewer cardiovascular drugs following myocardial infarction than men and non-Hispanic whites: the Corpus Christi Heart Project, 1988-1990. *J Clin Epidemiol*. 1996; 49(3):279-87.

Herlitz J. Comparison of lisinopril versus digoxin for congestive heart failure during maintenance diuretic therapy. The Lisinopril-Digoxin Study Group. *Am J Cardiol*. 1992;70(10):84C-90C.

Herlitz J, Waagstein F, Lindqvist J, Swedberg K, Hjalmarson A. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg Metoprolol Trial). *Am J Cardio*. 1997;80(9B) p40J-44J.

Herrlin B, Nyquist O, Sylven C. Induction of a reduction in haemoglobin concentration by enalapril in stable, moderate heart failure: a double blind study. *Br Heart J.* 1991;66(3):199-205.

Herrlin B, Sylven C, Nyquist O, Edhag O. Short term haemodynamic effects of converting enzyme inhibition before and after eating in patients with moderate heart failure caused by dilated cardiomyopathy: a double blind study. *Br Heart J.* 1990;63(1):26-31.

Higginbotham MB, Morris KG, Bramlet DA, et al. Long-term ambulatory therapy with prazosin vs. placebo for chronic heart failure: relation between clinical response and left ventricular function at rest and during exercise. *Am J Cardiol*. 1983;52:782-788.

Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. *JAMA*. 2000;283(10);1295-302.

Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, KjekshusJ, et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet*. 1999;353(9169):2001-2007.

Hobbs RE. Results of the ATLAS study. High or low doses of ACE inhibitors for heart failure? *Cleve Clin J Med*. 1998;65(10):539-42.

Hood WB Jr, Youngblood M, Ghali JK, Reid M, Rogers WJ, Howe D, et al. Initial blood pressure response to enalapril in hospitalized patients (Studies of Left Ventricular Dysfunction [SOLVD]). *Am J Cardiol*. 1991;68(15):1465-8.

The HOPE study investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. *Can J Cardiol*. 1996;12(2):127-37.

Houghton AR, Harrison M, Cowley AJ. Haemodynamic, neurohumoral and exercise effects of losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy. Evaluation of Losartan in the Elderly. *Eur J Heart Fail*. 1999;1(4):385-93.

Hughes CV, Wong M, Johnson G, Cohn JN. Influence of age on mechanisms and prognosis of heart failure. The V-HeFT VA Cooperative Studies Group. *Circulation*. 1993;87(6 Suppl):VI111-7.

Hypertension detection and follow-up program cooperative group. Race, education, and prevalence of hypertension. *Am J Epidemiol*. 1977;106:351-361.

The International Steering Committee. Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). *Am J Cardio*. 1997;80(9B) p54J-58J.

Jansen RW, Gurwitz JH. Controversies surrounding the use of beta-blockers in older patients with cardiovascular-disease. *Drugs & Aging*. 1994;4(N3):175-183.

Jerie P, Kremer HJ, Uhlir O, Widimsky J. [A Czech and Slovak interventional study of spirapril (the CASSIS study). A randomized, double-blind, multicenter, placebo-controlled study in chronic heart failure]: <Original> Ceska a slovenska intervencni studie se spiraprilem (studie CASSIS). Randomizovana, dvojiteslepa, multicentricka studie, kontrolovana aktivne i placebem chronickeho srdecniho selhani. Za resitele studie CASSIS. *Vnitrni Lekarstvi*. 1997;43(6);351-8.

Johnstone D, Limacher M, Rousseau M, Liang CS, Ekelund L, Herman M, et al. Clinical characteristics of patients in studies of left ventricular dysfunction (SOLVD). *Am J Cardiol*. 1992;70(9):894-900.

Joy M, Hubner PJ, Thomas RD, et al. Long term use of enalapril in the treatment of patients with congestive heart failure. *Int J Cardiol*. 1987;16:137-44.

Just H, Drexler H, Taylor SH, Siegrist J, Schulgen G, Schumacher M. Captopril versus digoxin in patients with coronary artery disease and mild heart failure. A prospective, double-blind, placebo-controlled multicenter study. The CADS Study Group. *Herz*. 1993;18 Suppl 1 p436-43.

Kennedy HL, Brooks MM, Barker AH, Bergstrand R, Huther ML, Beanlands DS, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. *Am J Cardiol*. 1994;74(7):674-80.

Keren G, Pardes A, Eschar Y, Koifman B, Scherez J, Geleranter I, et al. One-year clinical and echocardiographic follow-up of patients with congestive cardiomyopathy treated with captopril compared to placebo. *Israel Journal of Medical Sciences*. 1994;30(1);90-8.

Kjekshus J, Swedberg K. Enalapril for congestive heart failure. *Am J Cardio*. 1989;63(8);26D-32D.

Kleber FX, Laube A, Osterkorn K, et al. Captopril in mild to moderate heart failure after 18 months: effects on morbidity and mortality. *JACC*. 1987;9:42A (Abstr).

Kleber FX, Niemoller L, Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial. *British Heart Journal*. 1992;67(4):289-96.

Kleber FX, Reindl I, Wenzel M, Rodewyk P, Beil S, Kosloswki B, et al. Experiences with ACE inhibitors early after acute myocardial infarction. Rationale and design of the German Multicenter Study on the Effects of Captopril on Cardiopulmonary Exercise parameters post myocardial infarction (ECCE). *Herz*. 1993;18 Suppl 1:424-9.

Kleber FX, Sabin GV, Winter UJ, Reindl I, Beil S, Wenzel M, et al. Angiotensin-converting enzyme inhibitors in preventing remodeling and development of heart failure after acute myocardial infarction: results of the German multicenter study of the effects of captopril on cardiopulmonary exercise parameters (ECCE). *Am J Cardiol*. 1997;80(3A):162A-167A.

Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). *Am Heart J*. 1999;138(5 Pt 1);849-55.

Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. *N Engl J Med*. 1995;333(25);1670-6.

Kober L, Torp-Pedersen C, Ottesen M, Burchardt H, Korup E, Lyngborg K. Influence of age on the prognostic importance of left ventricular dysfunction and congestive heart failure on long-term survival after acute myocardial infarction. TRACE Study Group. *Am J Cardiol*. 1996;78(2):158-62.

Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. *Circulation*. 1992;86(2):431-8.

Konstam V, Salem D, Pouleur H, Kostis J, Gorkin L, Shumaker S, et al. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators. *Am J Cardiol.* 1996;78(8):890-5.

Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB Jr, Kohn RM, et al. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. *Am Heart J.* 1996;131(2):350-5.

Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, et al. Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. *Am Heart J.* 1994;128(2):358-64.

Krishnamoorthy V, Quintana H, Dali S, et al. Heart failure with preserved systolic function in African Americans: The role of diabetes mellitus and obesity. *Circulation.* 2000;102 (suppl 2)(18).

Krum H. Beta-blockers in heart failure. The new wave' of clinical trials. *Drugs.* 1999;58(2):203-10.

Krum H, Gu A, Wilshire-Clement M, Sackner-Bernstein J, Goldsmith R, Medina N, et al. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. *Am Heart J.* 1996;131(2):337-41.

Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. *Circulation.* 1995;92(6):1499-506.

Krum H, Shusterman N, MacMahon S, Sharpe N. Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy. Australia/New Zealand Heart Failure Research Collaborative Group. *J Card Fail.* 1998;4(4):281-8.

Krum H, Tonkin A, Trotter A, Burton R, Garrett J, Lane G, et al. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. *Circulation.* 1995;92(2):212-218.

Krumholz HM, Wang Y, Parent EM, Mockalis J, Petrillo M, Radford MJ. Quality of care for elderly patients hospitalized with heart failure. *Arch Intern Med.* 1997;157(19):2242-7.

Kukin ML, Mannino MM, Freudenberger RS, Kalman J, Buchholz-Varley C, Ocampo O. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. *J Am Coll Cardiol.* 2000;35(1):45-50.

Kumanyika S. Improving our diet - still a long way to go. *N Engl J Med.* 1996;335:236-52.

Lang RM, Elkayam U, Yellen LG, Krauss D, McKelvie RS, Vaughan DE, et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. *J Am Coll Cardiol.* 1997;30(4):983-91.

Lanska DJ, Peterson PM. Effects of interstate migration on the geographic distribution of stroke mortality in the United States. *Stroke.* 1995;26:554-61.

Lechat P, Escolano S, Golmard JL, Lardoux H, Witchitz S, Henneman JA, et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). *Circulation.* 1997;96(7):2197-205.

Lechat P, Garnham J, Desche P, et al. Efficacy and acceptability of preindopril in mild to moderate chronic congestive heart failure. *Am Heart J.* 1993;126:798-826.

Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized clinical trials. *Circulation.* 1998;98:1184-91.

Lee DK, Marantz PR, Devereux RB. Left ventricular hypertrophy in black and white hypertensives. Standard electrocardiographic criteria overestimate racial differences. *J Am Med Assoc.* 1992;267:3294-3299.

Leier CV, Huss P, Magorien RD, et al. Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. *Circulation*. 1983;67:817-822.

Lemarie JC. Multicenter Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Ramipril Administered Orally for 24 Weeks in the Treatment of Stable Chronic Congestive Cardiac Failure. (unpublished report) 1992.

Lewis BS, Rabinowitz B, Schlesinger Z, Caspi A, Markiewicz W, Rosenfeld T, et al. Effect of isosorbide-5-mononitrate on exercise performance and clinical status in patients with congestive heart failure. Results of the Nitrates in Congestive Heart Failure (NICE) Study. *Cardiology*. 1999;91(1):1-7.

Lewis GR. Lisinopril versus placebo in older congestive heart failure patients. *Am J Med*. 1988;85(3B):48-54.

Liao Y, Cooper RS, McGee DL. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. *JAMA*. 1995;273:1592-1597.

Lichstein E, Hager WD, Gregory JJ, Fleiss JL, Rolnitzky LM, Bigger JT Jr. Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure. The Multicenter Diltiazem Post-Infarction Research Group. *J Am Coll Cardiol*. 1990;16(6):1327-32.

Littler WA, Sheridan DJ. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group. *Br Heart J*. 1995;73(5):428-33.

Livingston IL. Social status, stress, and health: black Americans at risk. Livingston IL (editor). *Handbook of Black American Health*. Westport, Conn: Greenwood Press, 1994:236-52.

Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). *Am J Cardio*. 1992; 70(4):479-87.

Lombardi WL, Litwin SE. Angiotensin-converting enzyme inhibitors: congestive heart failure and beyond. *Coron Artery Dis*. 1999;10(6):361-8.

Lubsen J, Chadha DR, Yotof YT, Swedberg K. Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure. *Am J Cardio*. 1996;77(14):1191-1196.

Luparini R L, Celli V, Piccirillo G, Guidi V, Cacciafestam, Marigliano V. Carvedilol in elderly patients with chronic heart failure, a 12 weeks randomized, placebo controlled open trial. *Archives of Gerontology and Geriatrics*. 1999;29:275-282.

Maass L. Double-Blind Comparative Trial with Ramipril and Placebo in Patients with Heart Failure (NYHA Class III-IV) Stabilized on Digitalis and Furosemides. (unpublished report) 1991.

Maass L. Efficacy and Safety of Ramipril (HOE 498) in Patients with Congestive Heart Failure in a Double Blind Placebo Controlled Trial. (unpublished report) 1991.

Maass L. Evaluation of the Effect of Ramipril (HOE 498) on Exercise Duration, Invasive Cardiac Haemodynamics Profiles, and Safety in Patients with Congestive Heart Failure. (unpublished report) 1991.

MacFadyen RJ, Lees KR, Reid JL. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study. *Br Heart J*. 1991;66(3):206-11.

MacFadyen RJ, Lees KR, Reid JL. Double blind controlled study of low dose intravenous perindoprilat or enalaprilat infusion in elderly patients with heart failure. *Br Heart J*. 1993;69(4):293-7.

Maggioni AP, Anand I, Masson S, et al. Non-ischemic congestive heart failure without renin-angiotensin-aldosterone and adrenergic systems activation in South African Blacks in Val-HeFT. *Circulation*. 2000;102(18).

Magnani B. Converting enzyme inhibition and heart failure. *Am J Med*. 1988;84(3A):87-91.

Magnani B, Magelli C. Captopril in mild heart failure: preliminary observations of a long-term, double-blind, placebo-controlled multicentre trial. *Postgraduate Medical Journal*. 1986;62 (Suppl 1):153-8.

Magorien RD, Unverferth DV, Leier CV. Hydralazine therapy in chronic congestive heart failure. *Am J Med*. 1984;77:267-274.

Markham RV, Corbett JR, Gilmore A, et al. Efficacy of prazosin in the management of chronic congestive heart failure: a six-month randomized, double-blind, placebo-controlled study. *Am J Cardiol*. 1983;51:1346-1352.

Massie B, Bourassa M, DiBianco R, Hess M, Konstam M, Likoff M, et al. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. *Circulation*. 1985;71(5):963-71.

Massie BM, Berk MR, Brozena SC, Elkayam U, Plehn JF, Kukin ML, et al. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET). *Circulation*. 1993;88(2):492-501.

Massie BM, Cleland JG, Armstrong PW, Horowitz JD, Packer M, Poole-Wilson PA, et al. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators [published erratum appears in J Card Fail 1998 Jun;4(2):153]. *J Card Fail*. 1998;4(1):3-8.

Mathew J, Davidson S, Narra L. Etiology and characteristics of congestive heart failure in blacks. *Am J Cardiol*. 1996;78:1447-1450.

Mayet J, Shahi M, Foale RA. Racial differences in cardiac structure and function in essential hypertension. *Br Med J*. 1994;308:1011-1014.

McGarry R. Randomized, Double-Blind, Multicenter Study Comparing Benazepril to Digoxin and to Placebo as Add On Therapy to Diuretic in Patients with CHF, NYHA Class II-III During a 12-Week Treatment Period, GHBA-194. (unpublished report) 1991.

McGrath BP, Arnolda L, Matthews PG, Jackson B, Jennings G, Kiat H, et al. Controlled trial of enalapril in congestive cardiac failure. *British Heart Journal*. 1985;54(4):405-14.

McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. *Circulation*. 1999;100(10):1056-64.

McMurray JJ. Major beta blocker mortality trials in chronic heart failure: a critical review. *Heart*. 1999;82 (Suppl 4):IV14-22.

Meade TW, Brosovic M, Chakraborti R. Ethnic group comparisons of variables associated with ischemic heart disease. *Br Heart J*. 1978;40:789-795.

Metra M, Nodari S, Daloia A, Bontempi L, Boldi E, Deicas L. A rationale for the use of beta-blockers as standard treatment for heart failure. *Am Heart J*. 2000;139(N3. MAR):511-521.

Moorman PG, Hames CG, Tyroler HA. Socioeconomic status and morbidity and mortality in hypertensive blacks. Saunders E. (editor) *Cardiovascular Diseases in Blacks*. Philadelphia: F.A. Davis, 1991:179-94.

Mortality from congestive heart failure: United States. *Morb Mortal Wkly Rep*. 1994;43:77-81.

Moye LA, Pfeffer MA, Wun CC, Davis BR, Geltman E, Hayes D, et al. Uniformity of captopril benefit in the SAVE study: Subgroup analysis. *Eur Heart J*. 1994;15(SUPPL. B):2-8.

Mulligan IP, Fraser AG, Tirlapur V, Lewis MJ, Newcombe RG, Henderson AH. A randomized cross-over study of enalapril in congestive heart failure: haemodynamic and hormonal effects during rest and exercise. *Eur J Clin Pharmacol*. 1988;34(4):323-31.

Mulrow CD, Mulrow JP, Linn WD, Aguilar C, Ramirez G, et al. Relative efficacy of vasodilator therapy in chronic congestive heart-failure - implications of randomized trials. *JAMA*. 1988;259(N23):3422-3426.

Mylona P, Cleland JG. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. *Eur J Heart Fail.* 1999;1(2):197-200.

National Heart Lung and Blood Institute National Institutes of Health. Report of the Working Group on Research in Coronary Heart Disease in Blacks. Bethesda, MD: National Institutes of Health, 1994:1-94.

The NETWORK Investigators, Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. *Eur Heart J.* 1998;19(3):481-9.

Newman TJ, Maskin CS, Dennick LG, Meyer JH, Hallows BG, Cooper WH. Effects of captopril on survival in patients with heart failure. *Am J Med.* 1988;84(3A):140-4.

Nony P, Boissel JP, Girard P, Leizorovicz A, Lievre M, Chifflet R. Relative efficacy of angiotensin converting enzyme-inhibitors on mortality of patients with congestive-heart-failure: implications of randomized trials and role of the etiology (ischemic or nonischemic) of heart-failure. *Eur Heart J.* 1992;13(N8):1101-1108.

Northridge DB, Currie PF, Newby DE, McMurray JJ, Ford M, Boon NA, et al. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. *Eur J Heart Fail.* 1999;1(1):67-72.

Northridge DB, Rose E, Raftery ED, Lahiri A, Elder AT, Shaw TR, et al. A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure. *Eur Heart J.* 1993;14(3):403-9.

Nussberger J, Fleck E, Bahrmann H, Delius W, Schultheiss HP, Brunner HR. Dose-related effects of ACE inhibition in man: quinapril in patients with moderate congestive heart failure. The Study Group on Neurohormonal Regulation in Congestive Heart Failure: Lausanne, Switzerland; Berlin, Dusseldorf, Munich, Germany. *Eur Heart J.* 1994;15 Suppl D:113-22.

O'Connor CM, Gattis WA, Zannad F, McNulty SE, Gheorghiade M, Adams KF, et al. Beta-blocker therapy in advanced heart failure: clinical characteristics and long-term outcomes. *Eur J Heart Fail.* 1999;1(1):81-8.

Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. *J Am Coll Cardiol.* 1995;25(6):1225-31.

Oparil S, Bakir SE. Calcium antagonists in cardiovascular disease: clinical evidence from morbidity and mortality trials. *Drugs.* 2000;59(2):25-37.

Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. *N Engl J Med.* 1996;334(21):1349-55.

Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med.* 2001;344(22):1651-8.

Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. *Circulation.* 1996;94(11):2793-9.

Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. *N Engl J Med.* 1993;329(1):1-7.

Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. *Circulation.* 1999;100(23):2312-8.

Pahor M, Guralnik JM, Gambassi G, Bernabei R, Carosella L, Carbonin P. The impact of age on risk of adverse drug-reactions to digoxin. *J Clin Epidemiol.* 1993;46(N11):1305-1314.

Paolisso G, Gambardella A, Marrazzo G, Verza M, Teasuro P, Varricchio M, et al. Metabolic and cardiovascular benefits deriving from beta-adrenergic blockade in chronic congestive heart failure. *Am Heart J.* 1992;123(1):103-10.

Pappas G, Queen S, Hadden W, et al. The increasing disparity in mortality between socioeconomic groups in the United States, 1960 and 1986. *N Engl J Med*. 1993;329:103-9.

Parker AB, Azevedo ER, Baird MG, Smith SJ, Arnold JM, Humen DP, et al. ARCTIC: assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada. *Am Heart J*. 1999;138(5 Pt 1):843-8.

Pennell DJ, Ray SG, Davies G, Burgess M, Webster J, Slomka P, et al. The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure. *Int J Cardiol*. 2000;72(3):265-74.

Persson H, Rythe'n-Alder E, Melcher A, Erhardt L. Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol. *Br Heart J*. 1995;74(2):140-8.

Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med*. 1992;327(10):669-77.

Pfeffer MA, Lamas GA, Vaughan DF, et al. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. *N Engl J Med*. 1988;319:80-100.

Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators. *J Am Coll Cardiol*. 1993;22(6):1557-63.

Philbin EF, DiSalvo TG. Influence of race and gender on care process, resource use, and hospital-based outcomes in congestive heart failure. *Am J Cardiol*. 1998;82:76-81.

Philbin EF, Santella RN, Rocco TA Jr. Angiotensin-converting enzyme inhibitor use in older patients with heart failure and renal dysfunction. *JAGS*. 1999;47(3):302-308.

Pitt B, Poole-Wilson P, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II. *J Card Fail*. 1999;5(2):146-54.

Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. *Lancet*. 2000;355(9215):1582-7.

Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet*. 1997;349(9054):747-52.

Pitt B, Yusuf S, for the SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD) subgroup results. *J Am Coll Cardiol*. 1992; 19:215A.

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med*. 1999;341(10):709-17.

Plehn JF, Krause-Steinrauf H, Anand IS, et al. Effect of race on cause-specific cardiovascular mortality in BEST. *Circulation*. 2000;102 (suppl 2)(18).

Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML. Usefulness of bucindolol in congestive heart failure. *Am J Cardiol*. 1990;66(5):603-7.

Pouleur H. Results of the treatment trial of the studies of left ventricular dysfunction (SOLVD). The SOLVD Investigators. *Am J Cardio*. 1992;70(10):135C-136C.

Pouleur H, Rousseau MF, Melin J, Marchandise B, Schroeder E, Ahn S, et al. Studies of left ventricular dysfunction (SOLVD) - rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. *Am J Cardio.* 1990;66(3):315-322.

Pouleur H, Rousseau MF, Oakley C, Ryden L. Difference in mortality between patients treated with captopril or enalapril in the Xamoterol in Severe Heart Failure Study. *Am J Cardiol.* 1991;68(1):71-4.

Pouleur HG, Konstam MA, Udelson JE, Rousseau MF. Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction. The SOLVD Investigators. *J Am Coll Cardiol.* 1993;22(4 Suppl A):43A-48A.

Pousset F, Copie X, Lechat P, Jaillon P, Boissel JP, Hetzel M, et al. Effects of bisoprolol on heart rate variability in heart failure. *Am J Cardiol.* 1996;77(8):612-7.

Powers ER, Chiaramida A, DeMaria AN, Giles TD, Hackshaw B, Hart W, et al. A double-blind comparison of lisinopril with captopril in patients with symptomatic congestive heart failure. *J Cardiovasc Pharmacol.* 1987;9 Suppl 3:S82-8.

The Randomized Aldactone Evaluation Study (RALES) Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure *Am J Cardio.* 1996;78(8) p902-7.

Regitz-Zagrosek V, Leuchs B, Krulls-Munch J, Fleck E. Angiotensin-converting enzyme inhibitors and beta-blockers in long-term treatment of dilated cardiomyopathy. *Am Heart J.* 1995;129(4):754-61.

Remes J, Nikander P, Rehnberg S, Halinen MO, Kuikka J, Lansimies E, et al. Enalapril in chronic heart failure, a double-blind placebo-controlled study. *Annals of Clinical Research.* 1986;18(3):124-8.

Remme WJ, Krayenbuhl HP, Baumann G, Frick MH, Haehl M, Nehmiz G, et al. Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group. *Eur Heart J.* 1994;15(7):947-56.

The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. *Circulation.* 2000;101(4):378-84.

Richardson A, Bayliss J, Scriven AJ, Parameshwar J, Poole-Wilson PA, Sutton GC. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. *Lancet.* 1987;2(8561):709-11.

Riegger GA. The effects of ACE inhibitors on exercise capacity in the treatment of congestive heart failure. *J Cardiovasc Pharmacol.* 1990;15 Suppl 2:S41-6.

Risler T, Braun U, Klarner HG, Muller-Schauenburg W, Heitkamp HC, Brilla GG, et al. [Comparison of lisinopril and captopril in treatment of severe heart failure (NYHA III-IV) in high risk patients. Preliminary results of the trial]. *Z Kardiol.* 1991;80 Suppl 2:40-3.

Rochon PA, Tu JV, Anderson GM, Gurwitz JH, Clark JP, Lau P, et al. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction. *Lancet.* 2000;356(N9230. AUG 19):639-644.

Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, et al. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators. *J Am Coll Cardiol.* 1994;23(2):393-400.

Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. *Lancet.* 2000;356(9230):615-20.

Rucinska EJ. A Double Blind Placebo Controlled Study to Evaluate the Effects of Enalapril in Patients with Chronic Heart Failure. (unpublished report) 1991.

Rucinska EJ. Enalapril vs. Placebo in Previously Untreated Patients with CHF. 1991.
Rucinska EJ. Lisinopril First-Line Therapy in CHF. (unpublished report) 1991.

Rucinska EJ, Small R, Irvin J. High-risk patients treated with enalapril maleate: safety considerations. *Int J Cardiol*. (unpublished report) 1989;22(2):249-59.

Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, et al. Effects of captopril on ischemic events after myocardial infarction: Results of the survival and ventricular enlargement trial. *Circulation*. 1994;90(4 I):1731-1738.

Ryden L, Malmberg K. Benefits of ace inhibitors: what remains to be proven? *Eur Heart J Supplements*. 2000;2(NI. AUG):L3-L7.

Sanderson JE, Chan SK, Yip G, Yeung LY, Chan KW, Raymond K, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. *J Am Coll Cardiol*. 1999;34(5):1522-8.

Sanderson JE, Chan SK, Yu CM, Yeung LY, Chan WM, Raymond K, et al. Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol. *Heart*. 1998;79(1):86-92.

Sanderson JE, Chan WW, Hung YT, Chan SK, Shum IO, Raymond K, et al. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. *Br Heart J*. 1995;74(5):502-7.

Schofer J, Hobuss M, Aschenberg W, Tews A. Acute and long-term haemodynamic and neurohumoral response to nisoldipine vs. captopril in patients with heart failure: a randomized double-blind study. *Eur Heart J*. 1990;11(8):712-21.

Schofield PM, Brooks NH, Lawrence GP, Testa HJ, Ward C. Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine. *Br J Clin Pharmacol*. 1991;31(1):25-32.

Schwartz RS. Racial profiling in medical research. *N Engl J Med*. 2001;344(18):1392-3.

Scriven AJ, Lipkin DP, Anand IS, Sutton GC, Poole-Wilson PA. A comparison of hemodynamic effects of one-month oral captopril and enoximone treatment for severe congestive heart failure. *Am J Cardiol*. 1987;60(5):68C-71C.

Scriven AJ, Lipkin DP, Anand IS, Sutton GC, Poole-Wilson PA. Double-blind, randomised, cross-over comparison of oral captopril and enoximone added to diuretic treatment in patients with severe heart failure. *J Cardiovasc Pharmacol*. 1988;11(1):45-50.

Seedat YK. Is the pathogenesis of hypertension different in black patients? *J Hum Hypertens*. 1996;10 Suppl 3:S35-7.

Seedat YK. Ethnicity, hypertension, coronary heart disease and renal diseases in South Africa. *Ethn Health*. 1996;1(4):349-57.

Seedat YK. The prevalence of hypertension and the status of cardiovascular health in South Africa. *Ethn Dis*. 1998;8(3):394-7.

Seedat YK. Hypertension in black South Africans. *J Hum Hypertens*. 1999;13(2):96-103.

Seedat YK. Hypertension in developing nations in sub-Saharan Africa. *J Hum Hypertens*. 2000;14(10-11):739-47.

Seneviratne B, Moore GA, West PD. Effect of captopril on functional mitral regurgitation in dilated heart failure: a randomised double blind placebo controlled trial. *Br Heart J*. 1994;72(1):63-8.

Shanes JG, Wolfkiel C, Ghali J, Dierenfeldt BJ, Kondos GT, Bauman JL. Acute hemodynamic effects of pindolol and propranolol in patients with dilated cardiomyopathy: relevance of intrinsic sympathomimetic activity. *Am Heart J*. 1988;116(5 Pt 1):1268-75.

Sharpe DN, Murphy J, Coxon R, et al. Enalapril in patients with chronic heart failure: a placebo controlled randomized double-blind study. *Circulation*. 1984;70:271-8.

Sharpe DN, Murphy J, Smith H, et al. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. *Lancet*. 1988:255-9.

Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. *Am J Cardio*. 1996;77(11):1017-20.

Sigurdsson A, Amtorp O, Gundersen T, Nilsson B, Remes J, Swedberg K. Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group. *Br Heart J.* 1994;72(5):422-7.

Silke B, Tennet H, Fischer-Hansen J, Keller N, Heikkila J, Salminen K. A double-blind, parallel-group comparison of flosequinan and enalapril in the treatment of chronic heart failure. *Eur Heart J.* 1992;13(8):1092-100.

Simarro E, Rodriguez MA, Bayon J, Lastra JA, Prieto P, Suarez G, et al. [The effect of gallopamil and propranolol in patients with ischemic cardiopathy and moderate depression of ventricular function]. *Rev Esp Cardiol.* 1995;48(11):741-5.

Simpson K, Jarvis B. Lisinopril: a review of its use in congestive heart failure. *Drugs:*2000;59(5):1149-67.

Singh V, Christiana J, Frishman WH. How to use calcium antagonists in hypertension: putting the JNC-VI guidelines into practice. Joint National Committee for the Prevention, Detection, Evaluation and Treatment of High Blood Pressure. *Drugs.* 1999;58(4):579-87.

The SOLVD Investigators. Studies of left ventricula dysfunction (SOLVD) rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. *Am J Cardiol.* 1990;66:315-22.

The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med.* 1991;325(5):293-302.

Spargias KS, Hall AS, Greenwood DC, Ball SG. beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study. *Heart.* 1999;81(1):25-32.

Stamler J, Rhomberg P, Schonberger JA. Multivariate analysis of the relationship of the seven variables to blood pressure. *J Chron Dis.* 1975;28:527-548.

Suwa M, Ito T, Otake Y, Moriguchi A, Hirota Y, Kawamura K. Comparison of the therapeutic effects of the beta-blocking agent bisoprolol and the calcium-blocking agent diltiazem in patients with heart failure due to dilated cardiomyopathy. *Jpn Circ J.* 1996;60(10):767-73.

Swedberg K. Effects of ace-inhibition on renal-function in severe congestive-heart-failure. *Zeitschrift Fur Kardiologie.* 1991;80(S2):50-54.

Swedberg K, Amtorp O, Gundersen T, et al. Is maximal exercise testing a useful method to evaluate treatment of moderate heart failure? *Circulation.* 1991;57:226.

Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. *Circulation.* 1990;82(5):1730-6.

Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). *N Engl J Med.* 1992;327(10):678-84.

Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *Am J Cardio.* 1988;62(2):60A-66A.

Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. *Eur Heart J.* 1999;20(2):136-9.

Texter M, Lees RS, Pitt B, Dinsmore RE, Uprichard AC. The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention. *Cardiovasc Drugs Ther.* 1993;7(2):273-82.

Timmis AD, Bojanowski LM, Najm YC, Nelson DJ, Gosling RG. Captopril versus placebo in congestive heart failure: effects on oxygen delivery to exercising skeletal muscle. *Eur Heart J.* 1987;8(12):1295-304.

Tonkon M, Awan N, Niazi I, Hanley P, Baruch L, Wolf RA, et al. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group. *Int J Clin Pract.* 2000;54(1):11-4, 16-8.

Torp-Pedersen C, Kober L, Carlsen J. Angio-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study. *Am Heart J.* 1996;132(1 Pt 2 Su):235-43.

Tsuyuki RT, McAlister FA, Teo KK. Beta-blockers for congestive heart failure: what is the current consensus? *Drugs Aging.* 2000;16(1):1-7.

Uhlir O, Dvorak I, Gregor P, Malek I, Spinarova L, Vojacek J, et al. Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial. *J Card Fail.* 1997;3(4):271-6.

Uprichard A. A 12-Week Double Blind, Placebo Controlled Study to Determine the Efficacy and Safety of Orally Administered Quinapril Hydrochloride in Patients with Congestive Heart Failure (unpublished report) 1994.

Uprichard A. A 16-week Double Blind, Placebo-Randomized Placebo Controlled Multicenter Trial to Evaluate the Effects of Withdrawal of Quinapril Hydrochloride on Exercise Tolerance in Patients with Mild to Moderate Congestive Heart Failure. (unpublished report) 1994.

Uprichard A. An 18-Week Double Blind, Optional Titration, Multicenter Study to Compare the Efficacy and Safety of Orally Administered Quinapril Hydrochloride with Captopril and Placebo in Patients with Congestive Heart Failure. (unpublished report) 1994.

Van den Heuvel AF, Van Gilst WH, Van Veldhuisen DJ, De VriesRJM, Dunselman PHJM, Kingma JH. Long-term anti-ischemic effects of angiotensin-converting enzyme inhibition in patients after myocardial infarction. *J Am Coll Cardiol.* 1997;30(2):400-405.

van der Does R, Hauf-Zachariou U, Pfarr E, Holtbrugge W, Konig S, Griffiths M, et al. Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. *Am J Cardiol.* 1999;83(5):643-9.

van Veldhuisen DJ, Genth-Zotz S, Brouwer J, Boomsma F, Netzer T, Man, Veld AJ, et al. High-versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. *J Am Coll Cardiol.* 1998;32(7):1811-8.

Vedin A, Wikstrand J, Wilhelmsson C, Wallentin I. Left ventricular function and beta-blockade in chronic ischaemic heart failure. Double-blind, cross-over study of propranolol and penbutolol using non-invasive techniques. *Br Heart J.* 1980;44(1):101-7.

Viscoli CM, Horwitz RI, Singer BH. Beta-blockers after myocardial infarction: Influence of first-year clinical course on long-term effectiveness. *Ann Intern Med.* 1992;118(2):99-105.

Vitovec J, Spinar J. First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril. Slovak Investigator Group. *Eur J Heart Fail.* 2000;2(3):299-304.

Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. *Lancet.* 1993;342(8885):1441-6.

Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. *J Am Coll Cardiol.* 1998;32(5):1194-200.

Weber KT, Kinasewitz GT, West JS, et al. Long-term vasodilator therapy with trimazosin in chronic cardiac failure. *N Engl J Med.* 1980;303:242-250.

Webster MWI, Fitzpatrick MA, Hamilton EJ, et al. Effects of Enalapril on clinical status, biochemistry, exercise performance and haemodynamics in heart failure. *Drugs.* 1985;30(Suppl 1):74-81.

Wedel H, DeMets D, Deedwania P, et al. Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HR trial. *Am Heart J.* 2001;142:502-11.

Weedle PB, Poston JW, Parish PA. The use of digoxin in 55 residential homes for elderly people. *Postgraduate Medical Journal.* 1988;64(N750):292-296.

Weir MR, Gray JM, Paster R. Differing mechanisms of action in angiotensin-converting enzyme inhibition in black and white hypertensive patients. *Hypertension.* 1995;25:124-30.

Widimsky J, Kremer HJ, Jerie P, Uhlir O. Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active-controlled, double-blind multicentre trial in patients with congestive heart failure. *European J Clin Pharm.* 1995;49(1-2):95-102.

Wiklund I, Swedberg K. Some methodological problems in analyzing quality of life data in severe congestive heart failure patients. *JCRP* 1991;5(3):265-273.

Wiklund I, Waagstein F, Swedberg K, Hjalmarsson A. Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial. Metoprolol in Dilated Cardiomyopathy trial. *Cardiovasc Drugs Ther.* 1996;10(3):361-8.

Williams DR. Socioeconomic differentials in health: a review and redirection. *Soc Psychol Q.* 1990;53:81-99.

Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. *J Am Coll Cardiol.* 1993;21(5):1094-100.

Witchitz S, Cohen-Solal A, Dartois N, Weisslinger N, Juste K, Darmon J Y. Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties. The CELICARD Group. *Am J Cardio.* 2000;85(12):1467-71.

Wood AJJ. Racial differences in the response to drugs - pointers to genetic differences. *N Eng J Med.* 2001;344(18):1393-6.

Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. *Circulation.* 1991;84(6):2426-41.

Wright JT Jr, Kusek JW, Toto RD, Lee JY, Agodoa LY, Kirk KA, et al. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. *Control Clin Trials.* 1996;17(4 Suppl):3S-16S.

Xu C, Weifeng S, Mingzhou L, Lansheng G. Beneficial effects of captopril on prognosis in elderly patients with acute myocardial infarction. *Chin Med Sci J.* 1998;13(2):107-111.

Xu H, Sun M, Zhou H. [Changes of plasma endothelin-1 in patients with congestive heart failure and the influence of metoprolol]. *Hunan I Ko Ta Hsueh Hsueh Pao.* 1998;23(5):467-9.

Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. *N Engl J Med.* 2001;344(18):1358-65.

Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Lukas MA, Young ST. Response of black heart failure patients to carvedilol [abstract]. *J Am Coll Cardiol.* 1997;29:284A.

Young JB, Gheorghiade M, Uretsky BF, Patterson JH, Adams KF Jr. Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme. *J Am Coll Cardiol.* 1998;32(3):686-92.

Yusuf S. Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure. *Herz.* 1993;18 Suppl 1:444-8.

Yusuf S. Phase I results of the randomized evaluation of left ventricular dysfunction (RESOLVD) trial. *Am J Managed Care.* 1998;4(7 SUPPL.):S380-S383.

Yusuf S, Garg R, Mcconachie D. Effect of angiotensin-converting enzyme-inhibitors in left-ventricular dysfunction - results of the studies of left-ventricular dysfunction in the context of other similar trials. *J Cardiovasc Pharmacol.* 1993;22(S9):S28-S35.

Yusuf S, Lonn E, Bosch J, Gerstein H. Summary of randomized trials of angiotensin converting enzyme inhibitors. *Clinical and Experimental Hypertension*. 1999;21(N5-6. JUL-AUG):835-845.

Yusuf S, Nicklas JM, Timmis G, Breneman G, Jafri SM, Duvernoy WFC, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. *N Engl J Med*. 1992;327(10):685-691.

Yusuf S, Peto R, Lewis J, et al. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. *Prog Cardiovasc Dis*. 1985;27:335-71.

Yusuf S, Phil D, Sleight P, Pogue J, Bosch J, Davies R, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med*. 2000;342(N3. JAN 20):145-153.

Zannad F, Chati Z, Guest M, Plat F. Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Fosinopril in Heart Failure Study Investigators. *Am Heart J*. 1998;136(4 Pt 1):672-80.

Ziesche S, Rector TS, Cohn JN. Interobserver discordance in the classification of mechanisms of death in studies of heart failure. *J Cardiac Failure*. 1995;1(2):127-132.

Zwehl W, Rucinska E, for Lisinopril Chronic Heart Failure Investigators. Long-term effects of lisinopril in patients with chronic heart failure: a multicenter, placebo-controlled trial. Nicholls MG (ed). *A Focus on the Clinical Effects of a Long Acting ACE-Inhibitors/Heart Failure*. New York, NY: Raven Press, 1990:31-40.